Hospital
Coastal Carolina Medical Center, INC.
Coastal Carolina Medical Center, INC. was paid $6.93M by Medicaid between Jan 2018 and Jan 2024, across 121 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 21% of everything it billed.
33Billing provider infoCOASTAL CAROLINA MEDICAL CENTER, INC.
HARDEEVILLE, SC 29927
HARDEEVILLE, SC 29927
33aNPI1962472431assigned 01/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.93M
24GClaims213,919
24DCodes billed121
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#45 of 115
Median peer was paid$2.47M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,512 | $723K | |
| 2019 | 34,795 | $871K | |
| 2020 | 28,891 | $1.08M | |
| 2021 | 33,595 | $1.14M | |
| 2022 | 39,660 | $1.38M | |
| 2023 | 39,480 | $1.52M | |
| 2024incomplete | 3,986 | $219K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 21% | 12,351 | 10,618 | $1.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 18,930 | 17,660 | $856K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 8.0% | 2,541 | 2,439 | $557K |
| 81001 | 7.0% | 8,850 | 8,083 | $487K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.2% | 4,073 | 3,848 | $430K |
| J3490 | Unclassified drugs | 5.0% | 3,958 | 2,389 | $350K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 4.9% | 6,680 | 3,698 | $341K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.6% | 2,768 | 2,451 | $318K |
| 87070 | 4.2% | 2,793 | 2,739 | $290K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 11,834 | 10,802 | $184K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 5,331 | 3,478 | $178K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 1,748 | 1,688 | $160K |
109 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 694 | $157K |
| 81003 | 1.7% | 2,076 | $117K | |
| 82962 | 1.5% | 2,520 | $107K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 2,362 | $97K |
| 81025 | 1.4% | 5,119 | $95K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,310 | $81K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,881 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,696 | $59K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,019 | $42K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 443 | $40K |
| 80306 | <1% | 983 | $38K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,350 | $32K |
| 99285 | Emergency room visit (most serious) | <1% | 5,331 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,045 | $30K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,668 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,420 | $27K |
| A9150 | Non-prescription drugs | <1% | 1,370 | $26K |
| 73610 | <1% | 203 | $23K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,033 | $19K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,353 | $18K |
| 73562 | <1% | 233 | $18K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 24 | $16K |
| 84702 | <1% | 1,007 | $12K | |
| 87807 | <1% | 1,091 | $10K | |
| 73630 | <1% | 183 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,060 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,515 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,563 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,109 | $7K |
| 73030 | <1% | 90 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,627 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,383 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,029 | $6K |
| 94664 | <1% | 1,122 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 300 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 360 | $4K |
| 87088 | <1% | 3,663 | $3K | |
| 87210 | <1% | 112 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,940 | $2K |
| 96376 | <1% | 413 | $2K | |
| 74018 | <1% | 42 | $2K | |
| 83735 | <1% | 1,736 | $2K | |
| 87186 | <1% | 1,343 | $2K | |
| 73130 | <1% | 14 | $2K | |
| 85379 | <1% | 659 | $2K | |
| 72100 | <1% | 55 | $2K | |
| 84484 | <1% | 3,365 | $1K | |
| 87077 | <1% | 1,318 | $1K | |
| 73110 | <1% | 14 | $1K | |
| 0001A | <1% | 31 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $1K |
| 0002A | <1% | 23 | $791.09 | |
| 83690 | <1% | 2,890 | $725.03 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 428 | $708.04 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 492 | $606.39 |
| 85610 | <1% | 2,026 | $541.41 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,659 | $495.83 |
| 83880 | <1% | 835 | $476.25 | |
| 86850 | <1% | 262 | $473.54 | |
| 83605 | <1% | 1,125 | $470.68 | |
| 74022 | <1% | 12 | $456.57 | |
| 87040 | <1% | 841 | $451.47 | |
| 73502 | <1% | 13 | $436.70 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,981 | $414.39 |
| 84156 | <1% | 59 | $396.43 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 734 | $384.48 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 103 | $380.28 |
| 59025 | Fetal non-stress test | <1% | 176 | $341.60 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 52 | $290.24 |
| 93976 | <1% | 203 | $229.64 | |
| 71250 | <1% | 13 | $200.65 | |
| 84703 | <1% | 70 | $195.74 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 240 | $142.50 |
| 82550 | <1% | 534 | $115.03 | |
| 82150 | <1% | 70 | $112.28 | |
| 86900 | <1% | 1,122 | $87.15 | |
| 86901 | <1% | 1,241 | $69.14 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,816 | $67.44 |
| 80061 | Lipid panel | <1% | 14 | $53.12 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,500 | $42.38 |
| A9270 | Non-covered item or service | <1% | 157 | $34.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,178 | $25.48 |
| 82570 | <1% | 71 | $18.24 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 767 | $16.31 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 24 | $11.61 |
| 85730 | <1% | 824 | $8.10 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 354 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 134 | $0.00 |
| 85027 | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 72 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 57 | $0.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 15 | $0.00 |
| 76801 | 0% | 109 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 32 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 39 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 13 | $0.00 |
| 87147 | 0% | 16 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 41 | $0.00 |
| 86140 | 0% | 41 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 12 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 38 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,522 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 422 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 31 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 78 | $0.00 |
| 84550 | 0% | 53 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 78 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 32 | $0.00 |
| 82805 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGROTELUSCHEN, RON (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hilton Head Health System, L.P. | Hilton Head Island, SC | $4.44M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.